ketanserin has been researched along with Amentia in 5 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The binding of the selective 5-HT2 antagonist [3H]ketanserin has been investigated in the temporal cortex of patients with Alzheimer's disease (SDAT), Parkinson's disease (PD), senile dementia of Lewy body type (SDLT) and neuropathologically normal subjects (control)." | 3.68 | Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. ( Cheng, AV; Edwardson, JA; Ferrier, IN; Jabeen, S; McKeith, IG; Morris, CM; Perry, EK; Perry, RH; Sahgal, A, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kołaczkowski, M | 2 |
| Marcinkowska, M | 2 |
| Bucki, A | 2 |
| Pawłowski, M | 2 |
| Mitka, K | 1 |
| Jaśkowska, J | 1 |
| Kowalski, P | 1 |
| Kazek, G | 2 |
| Siwek, A | 2 |
| Wasik, A | 2 |
| Wesołowska, A | 2 |
| Mierzejewski, P | 2 |
| Bienkowski, P | 2 |
| Śniecikowska, J | 1 |
| Jastrzębska-Więsek, M | 1 |
| Partyka, A | 1 |
| Perry, EK | 2 |
| Marshall, E | 1 |
| Kerwin, J | 1 |
| Smith, CJ | 1 |
| Jabeen, S | 2 |
| Cheng, AV | 2 |
| Perry, RH | 2 |
| Ferrier, IN | 1 |
| Morris, CM | 1 |
| Sahgal, A | 1 |
| McKeith, IG | 1 |
| Edwardson, JA | 1 |
| Maloteaux, JM | 1 |
| Laterre, EC | 1 |
| Laduron, PM | 1 |
| Javoy-Agid, F | 1 |
| Agid, Y | 1 |
5 other studies available for ketanserin and Amentia
| Article | Year |
|---|---|
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; C | 2014 |
Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Benzamides; Dementia; Dose-Response Relationship, Drug; Drug Partial Agonism; Humans; Indol | 2015 |
Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia.
Topics: Acetylcholine; Aged; Aged, 80 and over; Autopsy; Biogenic Amines; Choline O-Acetyltransferase; Demen | 1990 |
Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Hallucinations; Humans; Ketanserin; Lewy Bodie | 1991 |
Decrease of serotonin-S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy.
Topics: Aged; Aged, 80 and over; Dementia; Humans; Ketanserin; Middle Aged; Parkinson Disease; Receptors, Se | 1988 |